These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 29630158)

  • 1. A case illustrating successful eradication of recurrent, aggressive basal cell carcinoma located in a scar with vismodegib.
    Lucero OM; Fitzmaurice S; Thompson C; Leitenberge J
    Dermatol Online J; 2018 Feb; 24(2):. PubMed ID: 29630158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC).
    Kwon GP; Ally MS; Bailey-Healy I; Oro AE; Kim J; Chang AL; Aasi S; Tang JY
    J Am Acad Dermatol; 2016 Jul; 75(1):213-5. PubMed ID: 27317518
    [No Abstract]   [Full Text] [Related]  

  • 3. Inoperable infiltrative basal cell carcinoma successfully treated with vismodegib.
    Zargari O; Azimi SZ; Geranmayeh S
    Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28631369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma.
    Ally MS; Aasi S; Wysong A; Teng C; Anderson E; Bailey-Healy I; Oro A; Kim J; Chang AL; Tang JY
    J Am Acad Dermatol; 2014 Nov; 71(5):904-911.e1. PubMed ID: 24929884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal cyst formation and hyperkeratosis in a patient treated with vismodegib for locally advanced Basal cell carcinoma.
    Reinders MG; Brinkhuizen T; Soetekouw PM; Kelleners-Smeets NW; Hamid MA; Mosterd K
    Acta Derm Venereol; 2015 May; 95(5):618-9. PubMed ID: 25425396
    [No Abstract]   [Full Text] [Related]  

  • 6. Vismodegib and surgery combined - effective treatment of locally advanced basal cell carcinoma.
    Paulsen JF; Øregaard JS; Nielsen AL; Gehl J; Venzo A
    Acta Oncol; 2016 Dec; 55(12):1492-1494. PubMed ID: 27448604
    [No Abstract]   [Full Text] [Related]  

  • 7. Unique Tumor Heterogeneity Within a Single Locally Advanced Basal Cell Carcinoma Resulting in a Partial Response Despite Continuous Vismodegib Treatment.
    Nayyar PM; Chang ALS; Sarin K; Ratner D
    Dermatol Surg; 2019 Apr; 45(4):608-610. PubMed ID: 30045109
    [No Abstract]   [Full Text] [Related]  

  • 8. Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus.
    Peris K; Licitra L; Ascierto PA; Corvò R; Simonacci M; Picciotto F; Gualdi G; Pellacani G; Santoro A
    Future Oncol; 2015; 11(4):703-12. PubMed ID: 25686123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
    Lyseng-Williamson KA; Keating GM
    Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
    Dessinioti C; Plaka M; Stratigos AJ
    Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete response is reversible upon vismodegib withdrawal and re-inducible upon vismodegib rechallenge in a patient with locally advanced basal cell carcinoma.
    Dessinioti C; Plaka M; Dimitrakopoulou A; Stratigos AJ
    J Eur Acad Dermatol Venereol; 2019 May; 33(5):e187-e188. PubMed ID: 30653740
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial.
    Fosko SW; Chu MB; Armbrecht E; Galperin T; Potts GA; Mattox A; Kurta A; Polito K; Slutsky JB; Burkemper NM; Hurley MY
    J Am Acad Dermatol; 2020 Apr; 82(4):946-954. PubMed ID: 31836564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vismodegib for periocular and orbital basal cell carcinoma.
    Gill HS; Moscato EE; Chang AL; Soon S; Silkiss RZ
    JAMA Ophthalmol; 2013 Dec; 131(12):1591-4. PubMed ID: 24136169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma.
    Axelson M; Liu K; Jiang X; He K; Wang J; Zhao H; Kufrin D; Palmby T; Dong Z; Russell AM; Miksinski S; Keegan P; Pazdur R
    Clin Cancer Res; 2013 May; 19(9):2289-93. PubMed ID: 23515405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
    Cirrone F; Harris CS
    Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449).
    Meani RE; Lim SW; Chang AL; Kelly JW
    Australas J Dermatol; 2014 Aug; 55(3):218-21. PubMed ID: 25117162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vismodegib for recurrent locally destructive basal cell carcinoma in a renal transplant patient.
    Koelblinger P; Dummer R; Laimer M; Hecht S; Bauer JW; Gaggl A; Kugler A
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e7-e8. PubMed ID: 28646606
    [No Abstract]   [Full Text] [Related]  

  • 18. Oral Hedgehog Pathway Inhibition as a Means for Ocular Salvage in Locally Advanced Intraorbital Basal Cell Carcinoma.
    Mathis J; Doerr T; Lin E; Ibrahim SF
    Dermatol Surg; 2019 Jan; 45(1):17-25. PubMed ID: 30586344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma with vismodegib.
    Iarrobino A; Messina JL; Kudchadkar R; Sondak VK
    J Am Acad Dermatol; 2013 Jul; 69(1):e33-4. PubMed ID: 23768306
    [No Abstract]   [Full Text] [Related]  

  • 20. Secondary Resistance to Vismodegib After Initial Successful Treatment of Extensive Recurrent Periocular Basal Cell Carcinoma with Orbital Invasion.
    Papastefanou VP; René C
    Ophthalmic Plast Reconstr Surg; 2017; 33(3S Suppl 1):S68-S70. PubMed ID: 26398246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.